Jungo Imanishi1, John Slavin2, Marcus Pianta3, Louise Jackett2, Samuel Y Ngan4, Takaaki Tanaka5, Chris Charoenlap5, Claudia DI Bella6, Peter F M Choong7. 1. Department of Orthopaedics, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia Department of Orthopaedic Oncology and Surgery, Saitama Medical University International Medical Center, Saitama, Japan Department of Surgery, University of Melbourne, Fitzroy, Victoria, Australia. 2. Department of Pathology, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. 3. Department of Medical Imaging, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. 4. Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, East Melbourne, Victoria, Australia. 5. Department of Orthopaedics, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. 6. Department of Orthopaedics, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia Department of Surgery, University of Melbourne, Fitzroy, Victoria, Australia. 7. Department of Orthopaedics, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia Department of Surgery, University of Melbourne, Fitzroy, Victoria, Australia Bone and Soft Tissue Tumour Unit, Peter MacCallum Cancer Centre, East Melbourne, East Melbourne, Victoria, Australia sarcoma@bigpond.net.au pchoong@unimelb.edu.au.
Abstract
BACKGROUND/AIM: Superficial myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) are highly associated with infiltrative growth (tail sign) and local recurrence, but the impact of preoperative radiotherapy is uncertain. PATIENTS AND METHODS: Eight consecutive superficial MFS and 10 superficial UPS cases treated with preoperative radiotherapy and surgery were reviewed. Pathological response, surgical margin and magnetic resonance imaging (MRI) were retrospectively evaluated. Oncological events were reported in a descriptive form. RESULTS: Pathologically, nearly-complete response was observed in six UPS cases. Tail sign was pathologically detected in 13 cases, eight of which remained viable. Among the eight cases with viable tail, three cases, including two with positive margin, locally recurred. No major discrepancy was observed between tail length on pre-treatment T1-weighted post-contrast, fat-saturated MRI and pathological tail length. CONCLUSION: Tail of superficial MFS and UPS can retain viability even after radiotherapy and cause local recurrence unless they respond to radiotherapy well. Wider resection including the tail on MRI is recommended. Copyright
BACKGROUND/AIM: Superficial myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) are highly associated with infiltrative growth (tail sign) and local recurrence, but the impact of preoperative radiotherapy is uncertain. PATIENTS AND METHODS: Eight consecutive superficial MFS and 10 superficial UPS cases treated with preoperative radiotherapy and surgery were reviewed. Pathological response, surgical margin and magnetic resonance imaging (MRI) were retrospectively evaluated. Oncological events were reported in a descriptive form. RESULTS: Pathologically, nearly-complete response was observed in six UPS cases. Tail sign was pathologically detected in 13 cases, eight of which remained viable. Among the eight cases with viable tail, three cases, including two with positive margin, locally recurred. No major discrepancy was observed between tail length on pre-treatment T1-weighted post-contrast, fat-saturated MRI and pathological tail length. CONCLUSION: Tail of superficial MFS and UPS can retain viability even after radiotherapy and cause local recurrence unless they respond to radiotherapy well. Wider resection including the tail on MRI is recommended. Copyright
Authors: Juan Pablo Zumárraga; Felipe Augusto Ribeiro Batista; André Mathias Baptista; Marcelo Tadeu Caiero; Luis Pablo de la Rosa Martino; Olavo Pires de Camargo Journal: Acta Ortop Bras Date: 2018 Impact factor: 0.513
Authors: Mitchell S Fourman; Duncan C Ramsey; Justin Kleiner; Anser Daud; Erik T Newman; Joseph H Schwab; Yen-Lin Chen; Thomas F DeLaney; John T Mullen; Kevin A Raskin; Santiago A Lozano-Calderón Journal: Ann Surg Oncol Date: 2021-06-18 Impact factor: 5.344